KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Aquestive Therapeutics (AQST) Total Liabilities (2017 - 2025)

Aquestive Therapeutics has reported Total Liabilities over the past 9 years, most recently at $194.1 million for Q4 2025.

  • Quarterly results put Total Liabilities at $194.1 million for Q4 2025, up 20.12% from a year ago — trailing twelve months through Dec 2025 was $194.1 million (up 20.12% YoY), and the annual figure for FY2025 was $194.1 million, up 20.12%.
  • Total Liabilities for Q4 2025 was $194.1 million at Aquestive Therapeutics, up from $167.7 million in the prior quarter.
  • Over the last five years, Total Liabilities for AQST hit a ceiling of $194.1 million in Q4 2025 and a floor of $113.7 million in Q1 2021.
  • Median Total Liabilities over the past 5 years was $162.0 million (2023), compared with a mean of $156.5 million.
  • Biggest five-year swings in Total Liabilities: surged 44.51% in 2021 and later dropped 6.67% in 2023.
  • Aquestive Therapeutics' Total Liabilities stood at $144.1 million in 2021, then rose by 21.85% to $175.6 million in 2022, then fell by 6.67% to $163.9 million in 2023, then dropped by 1.42% to $161.6 million in 2024, then increased by 20.12% to $194.1 million in 2025.
  • The last three reported values for Total Liabilities were $194.1 million (Q4 2025), $167.7 million (Q3 2025), and $166.3 million (Q2 2025) per Business Quant data.